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In total, 281 of the 7711 women who were initially treated for breast cancer between 1954 and 1983 at the Gustave Roussy Institute
developed a second malignant neoplasm (SMN) other than second primary breast cancer and nonmelanoma skin cancer at least 1
year after breast cancer treatment. We carried out a nested case–control study to determine the overall relationship between the
dose of radiotherapy received at a given anatomical site and the risk of SMN at the same site. In total, 75% of the cases of SMN were
previously treated by radiotherapy, as compared to 73% of the controls. In the irradiated patients, the median local dose was higher
among cases (3.1Gy) than among controls (1.3Gy). More than 40% of the irradiated patients received a local dose of less than 1Gy.
A purely quadratic relationship was observed between the dose of radiation received at an anatomical site and the risk of SMN at this
site. According to the quadratic model, the excess risk of SMN was 0.2% (95% CI 0.05–0.5%) when the target organ received 1Gy.
This risk did not differ significantly according to age at the time of radiotherapy (o40 vs X40 years). The risk of SMN was 6.7-fold
higher for doses of 25Gy or more than in the absence of radiotherapy. No carcinogenic effect of chemotherapy was observed and a
dose–effect relationship between the length of tamoxifen treatment and SMN occurrence was found. This relationship was limited
to endometrial cancers and did not modify the relationship with radiation dose. Our results suggest that high radiation doses slightly
increase the risk of second malignancies after breast cancer.
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Population- and hospital-based studies suggested that among
breast cancer survivors, the risk of developing a second cancer at
other sites is 10–40% higher than in the general population
(Harvey and Brinton, 1985; Rubino et al, 2000). Genetic and
hormonal factors may play a role in this increased risk, as indeed
may radiation, chemo- and hormonal treatments of breast cancer.
The risk of cancer following ionising radiation has been
extensively studied and is relatively well known compared to the
risks due to other carcinogens (UNSCEAR, 2000). However, little
data are available for breast cancer patients even though radiation
therapy is widely used to reduce the risk of local recurrence. The
relative risk of second malignant neoplasm (SMN) associated with
external radiotherapy is between 0.7 and 1.8 (Harvey and Brinton,
1985; Herring et al, 1986; Murakami et al, 1987; Lavey et al, 1990;
Andersson et al, 1991; Cuzick et al, 1994; Fisher and Anderson,
1994; Valagussa et al, 1994; EBCTCG, 2000; Tanaka et al, 2001).
The conditions in radiotherapy units delivering high doses to
limited volumes are quite different from those in the cohorts
studied to estimate the risk of ionising radiation (UNSCEAR,
2000). Consequently, predicting the risks of radiation for breast
cancer requires an estimate of the relationship between the
radiation dose at a given site and the risk of SMN at this site.
Owing to the heterogeneity of the distribution of the radiation dose
through the body, the overall role of radiotherapy in SMN risk can
only be directly investigated by studying this relationship for all
the sites of SMN together.
To this end, we performed a case–control study nested in a
cohort of 7711 women treated for breast cancer between 1954 and
1983. The general characteristics of this cohort, as well as results
for secondary lung cancer have been reported (Rubino et al, 2000,
2002). This is the first report concerning the dose of radiation
received for breast cancer treatment and the risk of overall second
cancer.
PATIENTS AND METHODS
Patients
Cases were defined as women who developed an SMN at least 1
year after the diagnosis of breast cancer, among a cohort of 7711
women treated for breast cancer at the IGR between 1954 and 1983.
We included all women with histologically confirmed SMN, except
those with contralateral breast cancer, nonmelanoma skin cancer
and second cancers of unknown origin. The 281 patients who met
these criteria were included in the case–control study (Table 1).
Each case was matched with two or three controls from the cohort.
Patients were matched for age at first cancer (76 years) and
period of treatment (1954–1963, 1964–1973, 1974–1983). Con-
trols had to be followed up over a period that was at least as long as
the interval between the breast cancer and SMN diagnosis in the
corresponding case (reference date). Received 2 January 2003; revised 9 May 2003; accepted 16 May 2003
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cancer and the radiotherapy, chemotherapy and hormonal therapy
received between the breast cancer diagnosis and the reference
date was collected from technical and medical records for each
case and control. We thereafter considered the treatment received
from the diagnosis of breast cancer until 1 year before the
reference date (i.e. the ‘useful period’).
Radiation dosimetry The individual dose was calculated
using Dos_EG, a software package that was developed at the
IGR for retrospective studies and described in detail elsewhere
(Grimaud et al, 1994; Diallo et al, 1996; Shamsaldin et al,
1997, 1998, 2000). The doses absorbed at 151 anatomical sites
during external beam radiotherapy were estimated for every
patient in the case–control study. The corresponding treatment
conditions, generator and energy were considered, including the
use of a shielding block, wedge modifications, field shapes and
field sizes.
To determine whether a dose–response relationship exists, we
determined local doses of radiation, defined as the cumulative dose
absorbed at the site of (or closest to the site of) the SMN for a case,
and at the same site for the matched controls during the useful
period. The location of each SMN was determined from medical
records. According to this location, one or more of the 151 points
estimates were used to estimate the local dose of irradiation
received by each case and their matched controls.
Dose reconstruction was not possible for 11 (5%) cases and 18
(4%) controls treated by external radiotherapy due to the absence
of technical data. For one control, who was treated by radiotherapy
for castration, the local dose of radiation was considered to be the
mean dose received at this site after a castration by radiotherapy in
the control group. For the other patients, regression analysis was
used to explore a correlation among the cases and the controls
between the dose received at the site of SMN (or equivalent site for
the controls) and both clinical characteristics and treatment
features. For 10 cases and 11 controls, a good fit was obtained
(R
240.4) and the local dose was calculated from the estimated
coefficients for each anatomic site among all the cases and the
controls, respectively. For one case and six controls, the mean dose
received at the anatomic site among, respectively, all the cases and
all the controls was attributed.
Chemotherapy Any chemotherapy for initial breast cancer or its
recurrence or distant metastasis prior to the occurrence of the
secondary cancer was recorded for the 281 cases, as was any
chemotherapy received before the reference date for the controls.
The details collected for each course or cycle of chemotherapy
included the name and total dose of each drug used. The doses of
each drug received by each case or control either as initial
treatment or for recurrences of the breast cancer (local relapses or
distant metastasis) during the useful period were summed per
cycle. Drugs were then classified into four categories according to
their known mechanism of action in cells, rather than according to
their chemical structure: electrophilic agents, spindle inhibitors,
inhibitors of nucleotide synthesis and topoisomerase II inhibitors.
To determine the total amount of drug in each treatment category,
we converted the dose of each chemotherapy agent from
milligrams into moles. This was carried out because one molecule
of a given drug generally has one active site, whatever its weight.
Even if a particular drug has more than one active site per
molecule, the error introduced by this hypothesis is probably
lower than that introduced when summing the weights.
Hormonal therapy Data concerning castration (by surgery or
radiotherapy), tamoxifen treatment and other treatments such as
progestational agents, oestrogen, androgen or corticoids were
collected. For each category, the total duration of treatment during
the useful period was calculated.
Methods
Cases and controls were compared using conditional logistic
regression methods (Breslow and Day, 1980). Generalised risk
models were used to evaluate the shape of the dose–response
relationship for radiation dose (Preston et al, 1991): linear and
quadratic increases in the risk of SMN with the radiation dose were
tested and the presence of a negative exponential term to take into
account a possible cell killing effect at very high dose was researched.
In these models, the odds ratio (OR) is expressed as follows:
Table 1 Number of cases of each type of SMN, mean age at breast cancer treatment and mean latency between breast cancer treatment and SMN
occurrence
Cancer site ICD-9 Number of Cases Mean age at breast cancer
treatment (min–max)
Mean latency in years
(min–max)
Oral cavity and
esophagus and larynx
140–150, 161 11 55 (40–70) 9 (2–25)
Stomach 151 15 58 (44–79) 9 (2–23)
Colon 153 33 57 (37–81) 10 (1–26)
Rectum 154 17 51 (32–75) 11 (1–26)
Liver+gall bladder 155–156 2 57 (49–65) 8 (1–14)
Pancreas 157 5 71 (58–80) 7 (1–16)
Lung and bronchus 162–163 11 50 (3–79) 15 (4–23)
Endometrium uterus 182 42 53 (34–76) 11 (1–33)
Cervix uterus 180 27 49 (16–323) 8 (2–6)
Vulva and vagina 184 3 68 (66–69) 12 (9–16)
Ovaries 183 28 50 (35–69) 11 (1–28)
Bladder 188 6 62 (38–80) 9 (3–16)
Kidney 189 10 55 (37–73) 10 (2–29)
Melanoma 172 14 53 (30–79) 13 (2–32)
Nervous system 191–192 1 40 13
Thyroid 193 8 48 (37–68) 9 (3–27)
Bone and soft tissue 170–171 14 55 (41–77) 11 (3–31)
Myeloma 203 5 58 (49–64) 13 (9–17)
Lymphoma 200–202 15 63 (44–87) 11 (1–30)
Leukaemia 204–208 14 56 (41–71) 11 (1–22)
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In order to compare our results with those obtained with a single
exposure, we used models that took into account the dose per
faction and the number of fractions. In these models, the OR
associated with n fractions delivering a given dose per fraction
dosef is expressed as follows:
OR ¼ Cst½1 þ nðadosef þ bdose
2
fÞðexpðgdosefÞÞ  ð2Þ
An equivalent formulation of the OR is described in two models
(3) and (4) where the OR is expressed as a function of the total
dose and the number of fractions,
OR ¼ Cst½1 þ nðadose=n þ bðdose=nÞ
2Þðexpðgdose=nÞ  ð3Þ
OR ¼ Cst½1 þð adose þð b=nÞdose
2Þðexpðgdose=nÞÞ  ð4Þ
It is noteworthy that these models show that the fractionation
effect, if it exists, concerns the quadratic and the exponential
terms, but not the linear model. The significance of parameters was
tested by comparing nested models. Confidence intervals of the
parameters were estimated by likelihood calculations. The analysis
was performed using the Epicure epidemiological software
(Preston et al, 1991).
RESULTS
Characteristics of the cases and controls
A significant global heterogeneity was evidenced between the cases
according to the type of SMN (Table 1) for age at breast cancer
diagnosis (P¼0.01) and for age at SMN (P¼0.01), but not for the
delay between breast cancer and SMN (P¼0.2). SMN of the
thyroid and cervix uterus occurred at an earlier age than the other
types of SMN, among patients who had their breast cancer earlier
(Table 1).
Cases and controls were on average 54 years old at the time of
breast cancer treatment (ranging from 28 to 87 years), which
occurred on average in 1976 (1954–1983). The SMN occurred on
average 10 years after breast cancer treatment (up to 33 years).
Clinical characteristics of cases and controls were very similar:
76% of cases and 78% of controls had a stage p2 (i.e. M0/N0/T0 to
T3, or M0/N1/T0 to T2) cancer, by the UICC classification; 12 cases
and 21 controls were M1 (five cases and 10 controls had a primary
bilateral breast cancer, and seven cases and 11 controls had
metastasis). At the time of breast cancer diagnosis, half of the cases
and controls had no ovarian activity.
About three-quarters of the cases and controls underwent
mastectomy and less than one-fifth underwent conservative
surgery (lumpectomy or partial mastectomy); 209 (74%)
of the cases and 443 (72%) of the controls received radiotherapy
(Table 2). Radiotherapy was performed with Cobalt-60
gamma rays in 96% of the cases and 97% of the controls,
associated with electron beams in 24% of the cases and 22%
of the controls. Only 3% of the cases and 5% of the controls were
treated with low-energy X-rays produced by orthovoltage
machines (200–250KV) and 3% of the cases and 2% of the
controls with megavoltage X-rays (4–20MeV). Although the
cumulative dose to the breast and the number of fractions were
very similar in cases and in controls, the local dose was about three
times higher among cases (3.1Gy in median) than controls
(1.3Gy).
In total, 10% of the cases and controls were treated by
chemotherapy. The treatment protocols associated mostly two or
more of the following drugs: cyclophosphamine, 5 fluorouracil,
methotrexate, adriamycin and vincristine. Each group of che-
motherapy drug was given to an approximately equal proportion
of cases and controls, with no major differences in the mean
number of moles administered between the two groups.
Table 2 Details of the breast cancer treatments received by the patients
Cases Controls
Treatment characteristics (N¼281) (N¼614)
Loco-regional treatments
Radiotherapy
a: number of patients(%) 209 (74) 443 (72)
Fractions: mean (range) 27 (2–78) 28 (4–189)
Dose (Gy) to the breast
b: median (min–max) 52.1 (19.7–112) 54.0 (12.4–117)
Dose (Gy) to the site of SMN
c: median (min–max) 3.1 (0.01–68.4) 1.3 (0.002–79.8)
Systemic treatments
Chemotherapy
d: number of patients (%) 29 (10) 62 (10)
Electrophilic agents 26 (9) 58 (9)
Spindle inhibitors 25 (9) 45 (7)
Inhibitors of nucleotide synthesis 29 (10) 60 (10)
Topoisomerase II inhibitors 19 (7) 40 (7)
Hormonal treatment
e: number of patients (%) 71 (25) 132 (22)
Tamoxifen 46 (16) 93 (15)
Progesterone 13 (5) 35 (6)
Oestrogens 6 (2) 11 (2)
Androgen 25 (9) 27 (4)
Corticoid 5 (2) 10 (2)
Other hormonal treatments 5 (2) 11 (2)
Castration: number of patients (%)
Radiotherapy 68 (24) 150 (24)
Surgery 8 (3) 24 (4)
aIncluding treatments for distant metastases and castration; 48 cases and 105 controls were treated with several machines and
the type of machine was unknown for 11 cases and 18 controls.
bCumulative dose of radiation received to the site of the breast
treated for a breast cancer.
cCumulative dose of radiation received to the same site of the breast for the matched controls.
dEach patient received one or more types of treatment.
Second cancer after breast cancer treatment
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25% of the cases and 22% of the controls. About 15% of the cases
and controls received tamoxifen, with a treatment duration about
two times higher among cases (43 months in median) than
controls (27 months). This hormone was either administered for
the initial treatment of advanced cancer among postmenopausal or
for the treatment of relapses. The other hormones administered
were mostly progesterone and androgens. Progesterone was
mainly prescribed to women around 50 years old, who were not
receiving any other hormone treatments, whereas androgens were
mostly given to older women in association with tamoxifen for the
treatment of distant metastases.
Ovarian function was suppressed in 76 cases and 174 controls,
by pelvic radiotherapy in 68 cases (24%) and 150 (24%) controls.
The remaining eight cases and 24 controls underwent surgery.
Risk associated with radiotherapy
The overall OR of SMN associated with initial radiotherapy was 1.1
(95% CI: 0.8–1.6). A significant dose–response relationship was
found between the radiation dose to the anatomic site of SMN and
the risk of SMN (Po0.01), as shown in Table 3. Different dose–
responses relationships were considered (Table 4). The best fit was
obtained for a purely quadratic dose–response relationship,
without a negative exponential term for cell killing at high doses.
Indeed, the deviance of the quadratic model (deviance¼631.0) was
lower than that of the linear model and was not significantly
reduced by the addition of a linear term (deviance¼630.6) or both
linear and exponential terms (deviance¼630.6). The estimated
excess odds ratio for a dose of 1Gy was 0.002 (95% CI: 0.0005–
0.005) with the quadratic model. Figure 1 illustrates the dose–
effect relationship with the expected values according to a
quadratic dose–effect model. These results were verified taking
the effects of latency, age at diagnosis of breast cancer, type of
SMNs and effect of fractionation into account successively.
The results were similar after excluding the 85 cases of SMN that
occurred during the first 5 years after breast cancer treatment and
their matched controls: the best fit was obtained with a purely
quadratic model and the OR at 1Gy estimated with a quadratic
model was similar to the previous estimate: 0.003 (95% CI:
 0.0006 to 0.007).
Only 26 cases were less than 40 years old at the time of breast
cancer treatment. Among these women and their 64 controls, the
overall OR associated with initial radiotherapy was 2.5 (95% CI:
0.7–11.4), not significantly different from that in older patients
(P¼0.2). In the same way, the dose–response for radiation dose
was not significantly different in these two groups (P¼0.3).
Table 3 Odds ratios (OR) of second cancer as a function of the local dose of radiation
Local radiation
dose in Gy
Number of
cases/controls
Mean dose
in controls
Unadjusted OR
(95% CI
b)
Adjusted OR
a
(95% CI
b)
Test of trend
c
P-value
0 72/171 0 1 (ref) 1 (ref)
c
]0–1[ 94/212 0.19 1.1 (0.8–1.7) 1.1 (0.7–1.6)
[1–5[ 20/56 2.7 0.9 (0.4–1.6) 0.8 (0.4–1.6)
[5–10[ 30/54 7.3 1.3 (0.7–2.5) 1.2 (0.6–2.2) o0.01
[10–15[ 30/69 12.9 1.1 (0.6–1.9) 1.1 (0.6–1.9)
[15–20[ 16/34 15.9 1.3 (0.6–2.8) 1.3 (0.6–2.8)
[20–25[ 4/3 22.9 4.5 (0.9–27.2) 4.0 (0.8–23.2)
X25 15/15 41.1 6.4 (1.8–31.4) 6.7 (1.9–33.2)
Any dose 209/443 6.1 1.14 (0.82–1.59) 1.11 (0.80–1.56)
aOR adjusted for duration of tamoxifen treatment in months and chemotherapy (Y/N).
b95% CI¼95% confidence interval.
cTest of trend using a quadratic dose–effect relation,
after adjustment for duration of tamoxifen treatment in months and chemotherapy (Y/N).
Table 4 OR models and regression coefficients of second cancer for the local dose of radiation in Gy, adjusted for chemotherapy administration (yes/no)
and for duration of tamoxifen treatment
Regression coefficients
Models b1 b2 c1 Deviance
Baseline: OR¼exp(a1chemo+a2tmx) — — — 642.2
Linear: OR¼exp(a1chemo+a2tmx) [1+b1(dose)] 0.04 — — 634.4
Quadratic: OR¼exp(a1chemo+a2tmx) [1+b2(dose dose)] — 0.002 — 631.0
Linear-quadratic: OR¼exp(a1chemo+a2tmx) [1+b1(dose)+b2(dose dose)]  0.03 0.003 — 630.6
Linear-quadratic-exponential: OR¼exp (a1chemo+a2tmx) [1+((b1(dose)+b2 (dose dose)) exp (g1 dose)]  0.02 0.003 0.01 630.6
Chemo¼chemotherapy; tmx¼tamoxifen.
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Figure 1 OR of second malignant neoplasm (SMN) as a function of the
radiation dose received to the site of the SMN for cases and the equivalent
site for controls (with 95% CI). The curves correspond to the estimated
excess of the OR of SMN as a quadratic function of the radiation dose
(dotted curves: upper and lower 95% CI).
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and 14 with soft tissue and bone cancer. A dose–response
relationship has previously been described for each of these two
types of SMN. After excluding these cancers, the OR for
radiotherapy was 1.0 (95% CI: 0.7–1.5), without a significant dose
effect–relationship (P¼0.3), and the OR at 1Gy estimated with a
quadratic model was 0.0006 (95% CI:  0.001 to 0.003). No
significant, or near significant, dose–response was evidenced for
any of the other sites of SMN.
A purely quadratic model fitted the OR as a function of the dose
per fraction (model (2)). This result was not modified when a
linear (P¼0.7) and/or an exponential term (P¼0.6) were added.
The excess of odds ratio at 1Gy per fraction was 0.034 (95% CI:
0.007–0.09) with a quadratic model.
Effect of chemotherapy
No carcinogenic effect of chemotherapy was evidenced: the OR
associated with chemotherapy was 0.8 (95% CI: 0.5–1.2) and none
of the four drug categories were significantly associated with the
occurrence of SMN, even after adjustment for radiotherapy and
hormonal therapy.
Effect of hormonal therapy
The overall OR of SMN associated with tamoxifen treatment was
1.2 (95% CI: 0.7–1.9). A significant dose–response relationship
was found between the cumulative length of treatment and the risk
of SMN occurrence (P¼0.03) as shown in Table 5. However, this
association was restricted to endometrial cancers, that is, 42 of the
281 cases. In this group, the risk of SMN was 21.3-fold higher (95%
CI: 2.4–563) after 4 years of treatment compared to in the absence
of such treatment. Among the cases with second malignancies at
other sites, the duration of tamoxifen treatment had no effect
(Table 5).
Interactions between radiotherapy and systemic
treatments
No significant interaction was observed between radiation dose
and chemotherapy or tamoxifen administration. The odds ratio for
a local dose of radiation higher than 1Gy associated with
chemotherapy was 1.0 (95% CI: 0.5–1.9), compared to a null or
lower radiation dose in the absence of chemotherapy (Table 6).
Similarly, the odds ratio associated with doses over 1Gy and
tamoxifen was 1.3 (95% CI: 0.7–2.3). The estimates of the radiation
dose–response relationship were not modified by the adjustment
for chemotherapy and/or duration of tamoxifen treatment.
DISCUSSION
Our case–control study of 281 cases of SMN and 614 controls,
nested in a cohort of 7711 women treated for breast cancer at the
IGR between 1954 and 1984 showed that radiation increased the
risk of SMN. A quadratic relationship was found between the dose
of radiation received at a given anatomical site and the risk of SMN
occurrence at this site. The radiation-induced risk was largely
limited to lung cancer and bone and soft-tissue sarcoma, and the
dose–response relationship was no longer significant when these
two types of cancer were excluded. No carcinogenic effect of
chemotherapy was observed and there was a dose–effect relation-
ship between the length of tamoxifen treatment and SMN
occurrence. This relationship was limited to endometrial cancers
and did not modify the relationship with radiation dose. This
study is the first report on the relationship between the dose of
Table 6 OR of SMN according to systemic treatment and radiotherapy dose received at the SMN site of the case and at the same site for matched
controls
Dose of radiotherapy at the SMN site
0–1Gy 41Gy Total
Systemic treatment OR (No.) OR (No.) OR (No.)
Chemotherapy
No 1a (152/357) 1.2 (100/195) 1b (252/552)
Yes 1.3 (14/26) 1.0 (15/36) 1.0 (29/62)
Tamoxifen
No 1a (140/327) 1.2 (95/194) 1b (235/521)
Yes 1.1 (26/56) 1.3 (20/37) 1.1 (46/93)
No.¼Number of cases of SMN/ number of controls. 1a¼Reference category for the risks according to radiotherapy dose and systemic treatment. 1b¼Reference category for
the risk of systemic treatment, adjusted for radiotherapy dose.
Table 5 OR of SMN as a function of the total duration of tamoxifen treatment, adjusted for radiation dose and chemotherapy administration (yes/no)
All SMNs All SMNs excluding endometrial cancer (N¼239) Endometrial cancer (N¼42)
Duration of tamoxifen
treatment in months
Cases/controls OR (95% CI) Cases/controls OR (95% CI) Cases/controls OR (95% CI)
None or less than 1 236/522 1 (ref)* 204/426 1 (ref)** 32/96 1 (ref)***
[1–24[ 20/52 0.9 (0.5–1.7) 19/39 1.0 (0.5–1.9) 1/13 0.3 (0.01–1.4)
[24–48[ 9/22 0.9 (0.4–2.1) 7/19 0.7 (0.3–1.7) 2/3 1.4 (0.2–9.0)
[48–72[ 8/15 1.2 (0.4–3.1) 9/15 1.2 (0.5–2.9) 7/3 13.1 (2.2–249)
X72 8/3 5.9 (1.6–28.2)}
*Test of trend¼Po10
 2; **test of trend¼P¼0.03; ***test of trend¼P¼0.4.
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overall second cancer.
The dose–response relationship observed has to be interpreted
carefully. We estimated the average relationship between the
radiation dose at a set of anatomical sites (or organs, if small and
equivalent to a point) and the risk of SMN at the same sites. In the
case of whole body homogeneous irradiation, this dose–response
relation would directly predict the overall excess cancer risk for
such a dose. In the case of radiotherapy, this dose–response
relationship is still an accurate estimate of the average dose–
response for all cancer sites together, but it cannot be used to
predict the overall risk of radiation-induced cancer in patients.
We estimated that the excess risk of SMN when 1Gy was
delivered to the target organ was 0.2% (95% CI: 0.05–0.5%) when
the total dose was delivered in an average of 28 fractions. This is
far from that estimated from risk coefficients established with
Hiroshima and Nagasaki (HN) survivors, even when the age of the
women in our cohort at the time of breast cancer treatment was
taken into account. For HN survivors, there is a linear relationship
between dose of radiation and risk of solid tumours and the excess
relative risk per Gy among women aged 30 years at the time of
irradiation is 79% for all solid cancers (UNSCEAR, 2000). The
excess relative risk decreases by 50% for each additional decade of
age at the time of irradiation and is thus about 10% at 55 years of
age. The risk we estimated for the total dose of radiation is an
estimation of the risk associated to the entire radiation treatment
in several fractions and is not directly comparable to the risk
induced by a single exposure to radiation. Conversely, the excess
risk we estimated at 1Gy per fraction, that is, 3.4% (95% CI: 0.7–
9%), which can be compared to that of a single exposure, is lower
but probably not statistically different from the estimation for HN
survivors (10%). In addition, due to the quadratic shape of the
relationship, this discrepancy reduces with increasing dose. Thus,
for example, for a dose per fraction of 2Gy, the excess OR we
estimated, that is, 14% (95% CI: 2.8–36%), is not significantly
different from that estimated from HN-survivors with a linear
model (20%).
In general, excess risks per dose unit in studies of cancer risk
following radiotherapy are lower than those estimated in HN
survivors (Little, 2001). Little investigated this finding in detail and
concluded that this discrepancy can largely be explained by cell
sterilisation effects, although other factors such as difference in
underlying cancer risk and dose fractionation effects may also
contribute (Little, 2001). Conversely, our results do not support a
role of cell sterilisation. This was nonsignificant, whatever the
model fitted. Instead, they support the hypothesis that this
discrepancy is due to dose fractionation.
The risk associated with radiotherapy in our case–control study
is lower than that previously estimated in a sub-cohort analysis
including 4416 women (Rubino et al, 2000): 1.1 vs 1.6. This
discrepancy is not due to overmatching, but is explained by the
patient selection in the sub-cohort. The low OR we estimated for
radiotherapy (yes/no), 1.1, is consistent with the low estimated
coefficient for dose–response, and with the general findings of 11
other studies on SMN incidence or mortality (0.7–1.8). Only three
studies (Herring et al, 1986; Lavey et al, 1990; Fisher and
Anderson, 1994), the smallest ones, which included less than 50
SMN cases, estimated a relative risk of above 1.5. The other studies
(Harvey and Brinton, 1985; Murakami et al, 1987; Andersson et al,
1991; Cuzick et al, 1994; Valagussa et al, 1994; EBCTCG, 2000;
Tanaka et al, 2001; Veronesi et al, 2002) included about 3500 SMN
incident cases or deaths and estimated a maximum relative risk of
1.2. The RR associated with radiotherapy generally estimated in
previous studies is probably very similar to our finding.
We did not find that the risk of SMN was increased by
chemotherapy administration. Chemotherapy was first used as
part of the treatment of breast cancer during the late 1970s.
Consequently, only a small proportion of the women in our study
(10%) received this treatment. At present, eight studies have
investigated the role of chemotherapy in the risk of all types of
SMN. In two studies (Lavey et al, 1990; Rubagotti et al, 1996),
which included a total of 59 SMN cases that occurred during an
average follow-up of 5 years, the relative risk associated with
chemotherapy was between 2 and 3. In the other six studies
(Herring et al, 1986; Murakami et al, 1987; Valagussa et al, 1987,
1994; Matsuyama et al, 2000; Tanaka et al, 2001), this risk ranged
from 0.5 to 1.05. Overall, there is currently no evidence that the
overall SMN risk is increased by the antineoplasic drugs
administered for breast cancer treatment. However, new drugs
are regularly introduced and no published study has a long enough
follow-up period to study the risk associated with recent drugs.
Tamoxifen is increasingly used as adjuvant therapy and reduces
recurrences and mortality among breast cancer patients as well as
the occurrence of contralateral breast cancers (EBCTCG, 1998). We
found a low increased risk associated with this hormonal therapy,
limited to endometrial cancer, as previously shown (Curtis et al,
1996; EBCTCG, 1998; Mignotte et al, 1998). Tamoxifen treatment
increases the risk of overall SMN by 0.7–1.2 depending on the
study (Fornander et al, 1989; Andersson et al, 1991, 1992; Rutqvist
et al, 1995; Curtis et al, 1996; Rubagotti et al, 1996; EBCTCG, 1998;
Newcomb et al, 1999; Tanaka et al, 2001).
In conclusion, our results suggest that radiotherapy plays a
small role in the overall risk of second malignancies after breast
cancer.
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